Why is LCIS Important—Pathological Review

Abeer M. Shaaban

Abstract
Purpose of Review Lobular carcinoma in situ (LCIS) encompasses classical LCIS and other rarer and more recently recognised variants, namely pleomorphic LCIS (PLCIS) and florid LCIS. Each of those entities has characteristic histological diagnostic criteria, different rates of underestimation of malignancy and recommended management. In addition, those lesions can mimic a number of benign and malignant breast lesions and can particularly be mistaken for ductal carcinoma in situ (DCIS). Accurate diagnosis of those lesions is critical to ensuring the appropriate patient management.

Recent Findings Several international guidelines refining the pathological classification, staging and management of those lesions have recently been updated. This review will provide an up-to-date pathological overview of the current knowledge of LCIS with emphasis on the multidisciplinary management implications.

Summary Close correlation between imaging and pathology in a multidisciplinary pathway is essential in LCIS management. Classical LCIS on core biopsy/vacuum-assisted biopsy (VAB) is coded as B3 and, if without discordant imaging, should further be sampled by vacuum-assisted excision (VAE). PLCIS should be coded and managed as per high-grade DCIS. Florid LCIS is a rare entity that is thought to be more aggressive than classical LCIS. Excision with clear margin is advised.

Keywords Lobular neoplasia · Upgrade rate · Carcinoma in situ · LCIS · PLCIS · Florid LCIS

Introduction and Terminology

The lobular carcinoma in situ terminology was first coined by Foote and Stuart in 1941 [1] as a form of cancer arising in mammary lobules, although the lesion was recognised earlier by James Ewing in 1919. The term lobular neoplasia was subsequently proposed by Haagenson in 1978 [2].

In situ lobular neoplasia encompasses a spectrum of lesions including atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS). Both comprise the characteristic neoplastic monomorphic cells depicting the lobular features, namely cellular discohesion and eccentric nuclei, and are commonly exhibiting intra-cytoplasmic vacuoles. The above description applied to classical LCIS that is recognised to be multifocal/multicentric (60–80%) [3] and bilateral (23–35%) [4, 5]. It has long been regarded as a marker of subsequent breast cancer risk (×8–10 increased risk compared with the general populations). Recent epidemiological and molecular data supports the lesion being a non-obligate precursor of breast cancer [6, 7].

More recently, other less common variants of LCIS have been recognised including pleomorphic (PLCIS) and florid LCIS. The diagnosis, core biopsy categorisation and management of those variants are different to those of classical LCIS and hence the importance of their correct classification. The diagnosis of LCIS can pose diagnostic challenges to the practising pathologist as the lesion can mimic a number of benign and malignant breast lesions or get misdiagnosed as ductal carcinoma in situ (DCIS).

This review will provide an up-to-date overview of the diagnostic features of the spectrum of lobular neoplasia lesions with emphasis on radiological–pathological correlation and management implications.

Epidemiology and Presentation

Classical LCIS is often diagnosed as an incidental microscopic finding although a small proportion calcifies and can
therefore be detected mammographically. Its precise incidence is difficult to ascertain, but the reported incidence is between 0.5 and 3.8% of all breast biopsies [2, 8]. Classical LCIS is a disease of pre-menopausal women. There is evidence, however, that PLCIS presents at a later age. A UK multicentre audit of 179 PLCIS patients showed a mean age at diagnosis of 60 years [9].

PLCIS and florid LCIS are often associated with comedo necrosis and calcification but can also present as mass lesions. The Surveillance, Epidemiology, and End Results Program (SEER) data showed an increase in LCIS incidence over the years, likely due to mammographic screening. The largest increase was noted in women over 50 years of age [10].

Data from the SEER Program showed that subsequent breast cancer after partial mastectomy occurred almost with equal frequencies in the same (46%) and contralateral (54%) breast [4]. A retrospective follow-up series, however, showed that subsequent breast cancer development occurs three times more likely in the breast harbouring ALH compared with the contralateral breast [11].

Microscopic Features

Characteristics of the Lobular Cells

The lobular cells of in situ and invasive lobular carcinoma are generally small, uniform cells and show evidence of cellular discohesion (loss of cellular contact) due to loss of the e-cadherin protein which functions as an adhesion molecule responsible for gluing cells together. This is an important and useful feature that enables pathologists to suspect/recognise the lobular morphology even at low microscopic power. Other features that support the lobular phenotype include pagetoid spread, eccentric plasmacytoid nuclei, inconspicuous nucleoli, scant cytoplasm and intracytoplasmic vacuoles (Fig. 1a).

LCIS commonly arises within terminal duct lobular units. The dyscohesive lobular cells distend mammary lobules and can also involve large ducts in a pagetoid fashion. This pagetoid pattern refers to the proliferation of the lobular cells between an inner compressed luminal epithelial layer and an outer myoepithelial layer (Fig. 1b). While pagetoid spread is often seen with LCIS, the phenomenon is not exclusive and can also be noted in DCIS lesions.

ALH versus LCIS

The differentiation between the two entities is quantitative. LCIS is diagnosed when more than half the acini in a terminal duct lobular unit are filled, distended and distorted by the lobular cells and ALH when the same type of cells fill less than half of the acini (Fig. 1c).

Classical LCIS versus PLCIS

Both entities show the characteristic lobular cells but PLCIS exhibits high-grade (grade 3) nuclei similar to the nuclei of high-grade DCIS. These commonly are large pleomorphic nuclei (>4 times the size of a lymphocyte), with conspicuous nucleoli and moderate/ample eosinophilic cytoplasm (Fig. 1d). The cells of PLCIS can show a striking apocrine appearance and this entity is designated as pleomorphic apocrine LCIS (PAL-CIS) (Fig. 1e). Similar to DCIS, PLCIS commonly calcifies and this is reflected histologically in the association of the lesion with central necrosis and luminal calcifications. Central comedo necrosis, although commonly seen, is not a pre-requisite for the diagnosis of PLCIS (Fig. 1d).

Classical LCIS versus Florid LCIS

Florid LCIS, previously called mass forming LCIS and classical LCIS with necrosis, describes distended mammary ducts by non-high-grade lobular cell nuclei. The cells are therefore similar to classical LCIS but involve large ducts with little or no intervening stroma and/or a ductal proliferation spanning a high-power microscopic field (equivalent to 40–50 intraductal cells) [12]. Florid LCIS can be associated with mammographic and histological calcification and/or comedo necrosis. Therefore, it can histologically mimic solid low and intermediate grade DCIS (Fig. 1f).

Florid LCIS versus PLCIS

Both show similar architecture, involve large mammary ducts, and are commonly associated with comedo necrosis and calcification. The only differentiating feature is the nuclear grade; if the nuclei are high grade, the lesion is designated as PLCIS; while if low/intermediate grade, the lesion is diagnosed as florid LCIS [13].

LCIS versus DCIS

LCIS can involve and distend large ducts resembling DCIS. Conversely, DCIS may colonise small lobules (cancerisation of lobules) and therefore mimics LCIS. DCIS lesions often show a mixture of architectural patterns such as micropapillary, cribriform and papillary. A solid atypical intraductal proliferation may therefore represent either DCIS or LCIS. Moreover, both lesions may coexist, sometimes within the same duct. The diagnosis of LCIS relies on a low index of suspicion and recognition of the lobular features within the proliferation. Loss of e-cadherin by immunohistochemistry can be used to confirm the lobular phenotype, as described below.
Role of Immunohistochemistry

The hallmark of lobular in situ and invasive carcinoma is the loss of e-cadherin expression by immunohistochemistry due to the loss of the e-cadherin glycoprotein. The latter is encoded by the CDH gene located on chromosome 16q22.1. The gene was first cloned in 1995 [14] and is recognised to be mutated in more than 50% of lobular carcinomas [15, 16].

The e-cadherin protein is expressed in normal mammary ductal epithelial cells, myoepithelial cells, DCIS and most invasive no special type (NST) carcinomas. The loss of e-cadherin expression is a helpful diagnostic test to confirm the lobular phenotype particularly in difficult cases and to confirm the non-classic variants’ diagnosis. Classical LCIS (Fig. 2a), florid (Fig. 2b), and PLCIS (Fig. 2c) show loss of e-cadherin expression.

It is important to note that e-cadherin may not be completely lost within in situ and invasive lobular carcinoma. Heterogeneous/aberrant/attenuated expression has been reported in 10–15% of lobular carcinomas [17, 18]. This is thought to be the result of a dysfunctional e-cadherin protein.

Fig. 1 Histological features of lobular neoplasia. a Terminal duct lobular unit distended and expanded with classical LCIS cells. The cells are uniform and dyscohesive with moderate eosinophilic cytoplasm and inconspicuous nucleoli. There are no high-grade features. b Pagetoid spread of lobular neoplasia cells into large ducts. The low-grade lobular cells are located between an inner compressed luminal epithelial layer and an outer myoepithelial layer. c Atypical lobular hyperplasia (ALH). Note the incomplete involvement of mammary lobules by the lobular cells and the associated blue luminal calcifications. d Pleomorphic LCIS (PLCIS): a large mammary duct contains a solid proliferation of large pleomorphic cells with dyscohesive nuclei and associated central comedo necrosis. e Pleomorphic apocrine LCIS (PAL-CIS): a high-grade atypical intraductal proliferation comprising pleomorphic cells with abundant eosinophilic granular cytoplasm resembling apocrine DCIS. The lobular phenotype is evident by the eccentric nuclei, intracytoplasmic vacuoles and discohesion. f Florid LCIS: several adjacent ducts with minimal intervening stroma distended by solid low to intermediate grade nuclei resembling solid DCIS. Note the cellular discohesion and plasmacytoid nuclei suggestive of a lobular phenotype.
In the author’s experience of second opinion practice, this phenomenon of incomplete loss of e-cadherin expression is not uncommon that can cause diagnostic difficulties for the referring pathologists as to the correct typing of the in situ and/or invasive carcinoma. In those cases, in addition to morphology, other immunohistochemistry, such as β-catenin and p120, can be used to confirm the lobular phenotype. Lobular cells show negative β-catenin (Fig. 2d) and cytoplasmic p120 expression [19, 20]. The latter is an indication of a non-functional e-cadherin protein.

As per the pathology guidelines [13, 21], the diagnosis of lobular neoplasia remains morphological with immunohistochemistry used as a supporting test particularly to differentiate variant LCIS from DCIS. The diagnosis of in situ and/or invasive lobular neoplasia should not solely be based on the e-cadherin status. Mixed lesions comprising e-cadherin positive DCIS and e-cadherin negative LCIS do exist (Fig. 2e). It is also recognised that a proportion of the poorly differentiated ductal carcinoma is e-cadherin negative and those tumours were shown to be associated with poor prognosis [22].

### Molecular Profile

Molecular analysis confirmed that lobular neoplasia is clonal that shares its molecular profile with invasive lobular carcinoma supporting that it is a non-obligate precursor of breast cancer. CDH1 gene inactivation leading to the loss of e-cadherin expression/function is the hallmark of lobular neoplasia and occurs as an early event. Classical LCIS is estrogen and progesterone receptor (ER and PR) (Fig. 2f) strongly positive and HER2 negative. The lobular cells comprise a monomorphous population of luminal cells that is negative for basal cytokeratins (such as CK5, CK5/6, CK14). The combination of negative basal cytokeratin and strong and uniform ER expression can be used in the diagnostic setting to confirm the neoplastic nature of the atypical proliferation. Non high-grade DCIS shares the same expression pattern of ER and basal cytokeratins.

PLCIS is predominantly ER positive but can be ER negative and a small proportion is HER2 positive [9].
Apocrine variant of PLCIS, however, is often ER/PR negative (80% of cases) [23••]. The reported Her2 positivity in PLCIS ranged from 1 to 41% [24•]. Similar to classic LCIS, florid LCIS is ER/PR positive and HER2 negative [25•].

PLCIS and florid LCIS exhibit greater genetic instability when compared with classical LCIS. A recent next-generation sequencing study of PLCIS (n = 10) and florid LCIS (n = 6) and their synchronous invasive lobular carcinoma (n = 11) showed shared genetic mutations in the ERBB2 gene and clonal relationship between the three lesions [26••].

**Associated Lesions**

**LCIS in Structured Benign Lesions**

LCIS, and its variants, can colonise pre-existing benign lesions such as fibroadenomas (Fig. 3a), intraduct papillomas, sclerosing adenosis, radial scars and collagenous spherulosis (Fig. 3b, c). This may pose diagnostic difficulties since the complex appearances may mimic DCIS and/or invasive carcinoma. E-Cadherin immunohistochemistry can help highlight the lobular component (Fig. 3c). Smooth muscle immunohistochemistry, such as p63 and SMM, is useful to confirm the presence of surrounding myoepithelial layer thus excluding invasive carcinoma. For an overview of the useful immunohistochemistry for LCIS diagnosis and its differentiation from mimics, see Pinder and Shaaban [13].

**Low Nuclear Grade Neoplasia and Rosen Triad**

Classical LCIS shares similar morphological and molecular features with a range of benign, atypical, low grade in situ and invasive carcinomas. Rosen triad describes the association between lobular neoplasia, columnar cell lesions and tubular carcinoma [27].

Lobular neoplasia nuclei resemble and commonly coexist with low-grade DCIS, invasive lobular, mucinous and low-grade NST carcinoma [28]. This highlights the importance of further tissue sampling following the diagnosis of classical lobular neoplasia as the lesion may be upgraed to in situ or invasive carcinomas of those low-grade types.

The most common invasive histological type associated with lobular neoplasia is invasive lobular carcinoma (classical and pleomorphic). The largest UK-based multicentre study of PLCIS showed that the associated invasive carcinoma was lobular in 117 out of 130 cases (90%). The invasive lobular carcinoma existed either in a pure form or admixed with other invasive carcinoma types and the majority (71%) were of grade 2 differentiation. The associated carcinomas were often ER positive (92%) with only a minority (7.3%) showing HER2 positivity [9••].

Similar to classic LCIS and PLCIS, invasive lobular carcinoma grades 2 and 3 was the most common histological type associated with florid LCIS [25•, 29••]. In their series of 61 PLCIS and 24 florid LCIS diagnosed over 20 years, Shamir et al. reported that 84% of the cancers were lobular, followed by mixed ductal/lobular carcinoma (13%) with pure invasive ductal carcinoma representing only 3% of cases [24•].

**Upgrade Rate**

Further sampling, by VAE or surgical excision, following the diagnosis of LCIS reveals in situ and/or invasive carcinoma in a significant proportion of lesions. A review of the literature by Hussain and Cunnick showed an average upgrade rate of 21.3% for classical LCIS [30].
In their study of 76 examples of non-classical LCIS from 75 patients, Nakhlis et al. reported an upgrade rate to in situ (n = 10) or invasive malignancy (n = 17) of 36%. No predictors of upgrade could be identified [31]. A study of 85 PLCIS and florid LCIS showed an upgrade rate to malignancy of 38% and 33%, respectively [24]. Similarly, a multicentre UK audit of 176 PLCIS examples including data from the Glacier study reported an upgrade rate of 31.8% when PLCIS was the most significant abnormality [9]. The upgrade rate to malignancy following the diagnosis of PLCIS, however, varied in the literature from as low as 18% [32] to as high as 65% [33] with an average of 33% [34].

Data on florid LCIS upgrade are rather limited and the few studies available generally reported on the combined florid and PLCIS outcome. A recent large multi-institutional study reported an upgrade rate of 39.7% for both lesions and a combined rate of 33.9% on reviewing the literature [29]. The author’s work of 17 florid LCIS lesions revealed an association with DCIS, PLCIS and invasive lobular carcinoma in 29.4%, 23.5% and 35.9% of cases, respectively [25].

The variability in the reported upgrade rate of lobular neoplasia may partly be due to the differences in the terminologies and the inconsistency in the histological diagnoses due to the relative recent recognition of the rare LCIS variants. In addition, the population of patients studied (screening versus symptomatic), family history, radiological–pathological concordance, method of sampling (VAE versus surgery) and the association with other high-risk lesions are all likely to impact on the findings. The recent pathology guidelines including the WHO Blue Book for breast tumours (2019) have clarified the diagnostic features and definition of each category. Previous terminologies such as ‘non classical LCIS’ or ‘variant LCIS’ are discouraged and should no longer be used [12].

**Pathological Staging of LCIS**

There has been a longstanding debate as to whether LCIS is a true in situ carcinoma or a marker of increased breast cancer risk. Unlike DCIS, it is not mandatory to excise classical LCIS with concordant imaging. PLCIS, however, is managed similar to high-grade DCIS by surgical excision with clear margin supporting its neoplastic nature [35].

The latest 8th edition of the TNM staging by AJCC (the American Joint Committee on Cancer) does not recognise LCIS, nor its variants, as in situ carcinoma and these lesions are no longer staged as pTis [36]. The latest edition of the WHO Blue Book for breast tumours refers to the TNM AJCC staging and also recognises that PLCIS should be treated by surgical excision as per the recommendations of several international guidelines [12].

In the UK, the current National Health Service Breast Screening Programme (NHSBSP) guidelines, and the pending update, regard LCIS and variants on surgical excisions as in situ carcinoma that are staged as pTis [21].

**Management of LCIS**

On the diagnostic sample, whether conventional core biopsy or vacuum-assisted biopsy (VAB), both ALH
and classical LCIS are coded as B3 (lesions of uncertain malignant potential). PLCIS, on the other hand, is regarded as high-grade in situ carcinoma (similar to high-grade DCIS) and is coded as B5a. There is no international consensus on the B coding of pure florid LCIS on core biopsy. In the UK, it is recommended to code those lesions as B4 to reflect the higher likelihood of co-existent invasive carcinoma [37•].

Management of LCIS and variants should be centred on clinicopathological correlation and discussion at the multidisciplinary/tumour board meetings [38•]. Those lesions without discordance are managed by further tissue sampling to exclude co-existent lesions such as PLCIS, DCIS or invasive carcinoma. While further sampling was traditionally achieved via diagnostic excision, this has largely been replaced worldwide by vacuum-assisted excision (VAE). Adequate sampling by vacuum biopsy is the recommendation of the Swiss guidelines (the second international consensus) [39••] that endorsed the recommendations of the first national consensus [40]) and UK guidelines [37•]. A summary of the management algorithm of lobular neoplasia is provided in Fig. 4.

An adequate VAE sample, as a guide, should weigh more than 4 g (unless the lesion is radiologically small and has wholly been sampled) [37•]. Chemoprevention using endocrine therapy, such as tamoxifen or aromatase inhibitors, has been proven to reduce the risk of breast cancer by more than 50% in randomised controlled trials [41] and can be used for the chemoprevention of breast cancer following the diagnosis of LCIS [42]. A survey of chemoprevention uptake revealed a rate of only 15% [43].

It is of note that no B-coding is required for VAE diagnoses since the samples are regarded as equivalent to surgical diagnostic excisions. This highlights the need for excellent communication between radiologists and pathologists to indicate the type and indication for the biopsy taken. The specimen should ideally be weighed (either in imaging or pathology) to assess for adequacy of sampling. If this is not feasible, then the information can be extrapolated from the number of cores sampled and the gauge of needle cores. The NHSBSP B3 pathology guidelines provide a useful table of different vacuum devices and the approximate target number of core biopsies to achieve adequate sampling [37•].

Complete excision of the lesion is required following the diagnosis of PLCIS. This is also recommended for the management of florid LCIS in view of the current evidence supporting the association with more advanced lesions. PLCIS is reported as per DCIS including measurement of whole tumour size and distance to margins [21, 35].

Follow-up

There has been no international consensus on the frequency and/or duration of mammographic follow-up following the diagnosis of LCIS and collection of high-quality outcome data is important to provide evidence base guidance. The current UK and Swiss guidelines [37•, 39••] recommend an annual mammographic follow-up for 5 years for B3 lesions including LCIS. PLCIS and florid LCIS are on the other hand managed by open surgical excision followed by the standard mammographic follow-up as per DCIS.

Abbreviations

ALH, Atypical lobular hyperplasia; DCIS, Ductal carcinoma in situ; ER, Estrogen receptor; LCIS, Lobular carcinoma in situ; LN, Lobular neoplasia; NST, No special type carcinoma; PLCIS, Pleomorphic lobular carcinoma in situ; PAL-CIS, Pleomorphic apocrine lobular carcinoma in situ; PR, Progesterone receptor; SEER, The Surveillance, Epidemiology, and End Results Program; VAB, Vacuum-assisted biopsy; VAE, Vacuum-assisted excision

Acknowledgements

A.M.S. is supported by Birmingham Cancer Research UK Centre (C17422/A25154).

Declarations

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by the author.

Conflict of Interest A.M.S. declares that she has no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Papers of particular interest, published recently, have been highlighted as:
- Of importance
- Of major importance

1. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17(4):491–63.
2. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42(2):737–69.
3. Wheeler JE, Enterline HT, Roseman JM, Tomasulo JP, McIlvaine CH, Fitts WT Jr, et al. Lobular carcinoma in situ of the breast. Long-term follow up. Cancer. 1974;34(3):554–63.
4. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, et al. Bilateral risk for subsequent breast cancer after lobular
carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23(24):5334–41.

5. Anderson JA. Multicentric and bilateral appearance of lobular carcinoma in situ of the breast. Acta Pathol Microbiol Scand A. 1974;82(6):730–4.

6. Page DL, Dupont WD, Rogers LW. Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. Hum Pathol. 1988;19(2):201–7.

7. Page DL, Simpson JF. What is atypical lobular hyperplasia and what does it mean for the patient? J Clin Oncol. 2005;23(24):5432–3.

8. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer. 1990;66(6 Suppl):1326–35.

9. Masanhat YA, Husain E, Roylance R, Heys SD, Carder PJ, Ali H, et al. Pleomorphic LCIS: what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ. Breast. 2018;38:120–4.

This is the largest multicentre series of PLCIS. The UK data describe the presentation, imaging and outcome of PLCIS. Data are discussed in relation to the previously published literature. The work shows a larger onset of PLCIS compared with classical LCIS, frequent association of the two lesions, confirms that the most common type of invasive carcinoma associated with PLCIS is lobular carcinoma of grade 2 differentiation. Both PLCIS and the associated carcinoma are often ER positive and HER2 negative.

10. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomark Prev. 2005;14(4):1008–11.

11. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361(9352):125–9.

12. The WHO Classification of Tumours Editorial Board. WHO Classification of tumours – breast tumours. 5th ed: International Agency for Research On Cancer (IARC); 2019. This is the most important pathology international book reference in breast pathology. The lobular neoplasia section (pp. 68–74) is an excellent well-illustrated description of classical LCIS, PLCIS and florid LCIS. It provides the essential and desired criteria for diagnoses and accepted terminologies. The previous edition used the terminology of classic LCIS with necrosis to describe florid LCIS.

13. Pinder SE, Shaaban AM. In situ lobular proliferations of the breast, invited review. Mini symposium of breast pathology. Diagn Histopathol. 2018;24:58–63.

14. Bex G, Stroka V, van Hengel J, Molemans F, Bussemakers MJ, van Bokhoven A, et al. Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics. 1995;26(2):281–9.

15. Bex G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13(9):1919–25.

16. Vos CB, Cleton-Jansen AM, Bex G, de Leeuw WJ, ter Haar NT, van Roy F, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997;76(9):1131–3.

17. Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol. 2006;30(5):773–83.

18. Dabbs DJ, Schnitt SJ, Geyer FC, Weigel B, Baehner FL, Decker T, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):e1–11.

19. Dabbs DJ, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol. 2007;31(3):427–37.

20. Li X, Schwartz MR, Ro J, Hamilton CR, Ayala AG, Truong LD, et al. Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS. Int J Clin Exp Pathol. 2014;7(5):2551–7.

21. NHS Cancer Screening Programmes and the Royal College of Pathologists. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. 2016. https://www.rcpath.org/uploads/assets/7763be1c-d330-40e8-95d08f953752792a/G148_BreastDatasets-HistJun16.pdf. Accessed 5 April 2021.

22. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005;46(6):685–93.

23. Chen YY, Hwang ES, Roy R, Devries S, Anderson J, Wa C, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33(11):1683–94.

24. Shamir ER, Chen YY, Chu T, Pekmezci M, Rabban JT, Kngs G. Pleomorphic and florid lobular carcinoma in situ variants of the breast: a clinicopathologic study of 85 cases with and without invasive carcinoma from a single academic center. Am J Surg Pathol. 2019;43(3):399–408. A large single institution study of 61 PLCIS and 24 florid LCIS cases spanning 20 years. The association with invasive lobular carcinoma with which the variants shared the immunohistochemical profile us confirmed supporting a direct precursor role. Less frequent ER expression was noted in PLCIS due to the apocrine morphology. Both lesions were treated by complete excision with clear margins and frequently (58% of cases) by adjuvant endocrine therapy but without adjuvant radiotherapy.

25. Shaaban AM, Elgedredly N, Sharma N, Sundararajan S, Maurice Y, Loane J, et al. Radiological, histological features and outcome of classical lobular carcinoma in situ with comedo-necrosis; a multi institutional series. J Pathol. 2016;240(suppl S1):S16 A small multi-institutional UK series but reporting only on florid LCIS (n = 17) with full description of their imaging, presentation, associated lesions and outcome. Mammographic calcification was the most common presentation and the lesion was associated with malignancy in 53% of cases supporting that the lesion is more aggressive than classical LCIS.

26. Shamir ER, Chen YY, Kngs G. Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma. Mod Pathol. 2020;33(6):1078–91. A recent molecular profiling of 16 examples of both PLCIS and florid LCIS (n = 16) and 11 concurrent invasive lobular carcinomas. All were enriched for ERBB2 mutations and copy number alteration. In addition, PLCIS showed TP53 and FOXA1 mutations.

27. Brandt SM, Young GQ, Hoda SA. The “Rosen Triad”: tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. Adv Anat Pathol. 2008;15(3):140–6.

28. Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32(4):513–23.

29. Foschini MP, Miglio R, Fiore R, Baldovini C, Castellano L, Callagy G, et al. Pre-operative management of pleomorphic and florid lobular carcinoma in situ of the breast: report of a large multiinstitutional series and review of the literature. Eur J Surg Oncol. 2019;45(12):2279–86 A large international series of both PLCIS
and florid LCIS and good review of the previously published literature.

30. Hussain M, Cunnick GH. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast—a review. Eur J Surg Oncol. 2011;37(4):279–89.

31. Nakhlis F, Harrison BT, Giess CS, Lester SC, Hughes KS, Coopey SB, et al. Evaluating the rate of upgrade to invasive breast cancer and/or ductal carcinoma in situ following a core biopsy diagnosis of non-classic lobular carcinoma in situ. Ann Surg Oncol. 2019;26(1):55–61.

32. Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch Pathol Lab Med. 2010;134(7):1024–8.

33. Guo T, Wang Y, Shapiro N, Fineberg S. Pleomorphic lobular carcinoma in situ diagnosed by breast core biopsy: clinicopathologic features and correlation with subsequent excision. Clin Breast Cancer. 2018;18(4):e449–e54.

34. Pieri A, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: can the evidence guide practice? World J Clin Oncol. 2014;5(3):546–53.

35. Upcoming Dataset, Breast: Ductal Carcinoma in situ. 2021. Available from: http://www.iccr-cancer.org/datasets/upcoming-datasets. Accessed 5 April 2021.

36. Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC Cancer Staging Manual: breast cancer. Ann Surg Oncol. 2018;25(7):1783–5.

37. Upcoming Dataset, Breast: Ductal Carcinoma in situ. 2021. Available from: http://www.iccr-cancer.org/datasets/upcoming-datasets. Accessed 5 April 2021.

38. Shaaban AM, Sharma N. Management of B3 lesions—practical issues. Curr Breast Cancer Rep. 2019;11:83–8 A practical overview of issues related to B3 lesion management including lesion sizing, potential for full sampling on diagnostic biopsy, clip migration and appropriate coding.

39. Rageth CJ, O’Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat. 2019;174(2):279–96 The second European (Swiss) consensus guidelines for managing B3 lesions. Second line VAB is the recommended method apart from ADH and phyllodes tumour where surgical excision is recommended. Compared with the first consensus, more frequent follow-up for lobular neoplasia is advised.

40. Rageth CJ, O’Flynn EA, Comstock C, Kurtz C, Kubik R, Madjar H, et al. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat. 2016;159(2):203–13.

41. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.

42. Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158(8):604–14.

43. Trivedi MS, Coe AM, Vanegas A, Kukafka R, Crew KD. Chemoprevention uptake among women with atypical hyperplasia and lobular and ductal carcinoma in situ. Cancer Prev Res (Phila). 2017;10(8):434–41.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.